Morepen Laboratories Limited (MOREPENLAB) AI Stock Analysis

• Market Cap: ₹24.30B
• Dividend Yield: 0.46%
• Average Volume (3M): 88.30K
• Price to Earnings (P/E): 24.6
• Beta (1Y): 1.92
• Revenue Growth: -0.29%
• EPS Growth: -29.04%
• Country: IN
• Employees: 2,152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.75
• Shares Outstanding: 547,953,700
• 10 Day Avg. Volume: 126,704
• 30 Day Avg. Volume: 88,304
• PEG Ratio: 1.32
• Price to Book (P/B): 2.29
• Price to Sales (P/S): 1.45
• P/FCF Ratio: -28.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹45.00 ▲(3.57% Upside)

The overall stock score for Morepen Laboratories Limited is primarily influenced by its strong financial performance, despite challenges in profitability margins and cash flow management. Technical analysis indicates bearish momentum, which negatively impacts the score. The valuation suggests moderate pricing, but the low dividend yield limits income potential. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business sustainability and expansion.

Low Debt Profile

A low debt profile reduces financial risk and provides the company with greater flexibility to invest in growth opportunities and weather economic downturns.

Operational Efficiency

Strong operational efficiency suggests effective cost management and resource utilization, enhancing profitability and competitive positioning.

Negative Factors

Declining Profit Margins

Declining profit margins can signal rising costs or pricing pressures, potentially impacting long-term profitability and shareholder returns.

Liquidity Concerns

Liquidity concerns due to negative free cash flow can limit the company's ability to invest in growth and meet short-term obligations, affecting financial stability.

Profitability Challenges

Challenges in maintaining profitability margins may indicate operational inefficiencies or market challenges, impacting long-term financial health.

Morepen Laboratories Limited Business Overview & Revenue Model

Company Description

Morepen Laboratories Limited (MOREPENLAB) is a prominent Indian pharmaceutical and healthcare company that specializes in the development, manufacturing, and marketing of a diverse range of products including active pharmaceutical ingredients (APIs), finished formulations, diagnostic products, and herbal healthcare solutions. Operating primarily in the pharmaceutical sector, the company is known for its strong focus on research and development, enabling it to deliver high-quality products to both domestic and international markets.

How the Company Makes Money

Morepen Laboratories generates revenue through multiple streams, including the sale of finished pharmaceutical formulations, active pharmaceutical ingredients, and diagnostic products. The company has established a strong presence in the global market, supplying APIs to various pharmaceutical companies and leveraging its manufacturing capabilities to produce cost-effective and innovative healthcare solutions. Additionally, Morepen engages in partnerships with other pharmaceutical firms and healthcare providers to expand its product offerings and distribution networks. The company's revenue is also bolstered by its investment in research and development, leading to patents and proprietary products that enhance its market competitiveness.

Morepen Laboratories Limited Financial Statement Overview

Summary

Morepen Laboratories Limited exhibits strong revenue growth and a solid financial structure, with a low debt profile and effective equity utilization. However, profitability margins have shown a decline, and cash flow management poses challenges, with negative free cash flow highlighting liquidity risks.

Income Statement

The company has shown a consistent revenue growth over the years with a 7.5% increase from 2024 to 2025. The gross profit margin remains healthy at 34.4% for 2025, although the net profit margin has decreased to 6.5% compared to the previous year. The EBIT and EBITDA margins indicate a robust operational efficiency at 17.3% and 10.5% respectively for 2025. However, the drop in profitability margins signifies potential operational challenges.

Balance Sheet

The balance sheet reflects strong financial stability with a debt-to-equity ratio of 0.09 in 2025, indicating low leverage. Return on equity (ROE) stands at 10.2%, suggesting efficient utilization of equity. The equity ratio of 65.0% points to a sound capital structure. Overall, the company maintains a low-risk financial position with ample equity backing.

Cash Flow

The company faces challenges with cash flow management, as evidenced by a negative free cash flow in 2025, despite experiencing a significant increase in operating cash flow. The free cash flow to net income ratio is negative, indicating potential liquidity concerns. However, the operating cash flow to net income ratio of 0.27 suggests some degree of cash generation capability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.86B	18.30B	17.02B	14.18B	15.42B	11.75B
Gross Profit	6.35B	6.30B	6.18B	2.19B	4.81B	3.89B
EBITDA	1.57B	1.92B	1.73B	856.66M	1.57B	1.30B
Net Income	926.01M	1.18B	961.60M	386.75M	1.02B	970.86M
Balance Sheet
Total Assets	0.00	17.78B	12.93B	11.10B	10.70B	8.58B
Cash, Cash Equivalents and Short-Term Investments	1.27B	1.27B	169.45M	216.66M	158.03M	413.87M
Total Debt	0.00	1.05B	289.99M	251.64M	1.33B	1.37B
Total Liabilities	-11.87B	5.91B	4.46B	3.58B	4.92B	4.34B
Stockholders Equity	11.87B	11.56B	8.47B	7.53B	5.79B	4.25B
Cash Flow
Free Cash Flow	0.00	-919.76M	-79.61M	-1.37B	-1.25B	104.27M
Operating Cash Flow	0.00	320.57M	733.75M	-911.71M	-577.58M	508.26M
Investing Cash Flow	0.00	-3.22B	-833.00M	-465.09M	-316.79M	-703.51M
Financing Cash Flow	0.00	3.00B	52.05M	1.44B	663.34M	472.73M

Morepen Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 43.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Negative. The current price of 43.45 is below the 20-day moving average (MA) of 45.33, below the 50-day MA of 47.60, and below the 200-day MA of 53.70, indicating a bearish trend. The MACD of -1.34 indicates Positive momentum. The RSI at 30.12 is Neutral, neither overbought nor oversold. The STOCH value of 24.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MOREPENLAB.

Morepen Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOREPENLAB	57 Neutral	₹24.30B	24.64	―	0.46%	-0.29%	-29.04%
GUFICBIO	57 Neutral	₹32.77B	52.96	―	0.03%	7.78%	-34.68%
UNICHEMLAB	54 Neutral	₹33.06B	37.37	―	―	25.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	41 Neutral	₹26.48B	230.65	―	―	9.78%	50.78%

Morepen Laboratories Limited Corporate Events

Morepen Laboratories Releases Financial Results for September 2025

Morepen Laboratories Limited has announced the publication of its unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025. These results were approved by the Board of Directors on November 14, 2025, and have been published in the Financial Express and Jansatta newspapers. The announcement reflects the company’s commitment to transparency and regulatory compliance, potentially impacting its market perception and investor confidence.

Morepen Laboratories Subsidiary Forms Joint Venture in Medical Devices

Morepen Laboratories Limited announced that its subsidiary, Morepen Medipath Limited, has entered into a joint venture agreement with Bimedical FZE, a UAE-based entity, to form a new company focused on manufacturing, trading, and selling medical devices. This strategic move is expected to enhance Morepen’s position in the medical devices industry, potentially expanding its market reach and operational capabilities.